[Research Report] The noninvasive traumatic brain injury diagnostic equipment market is projected to grow from US$ 1.349 billion in 2022 to US$ 3.541 billion by 2030; it is estimated to record a CAGR of 12.8% during 2022–2030.

Market Insights and Analyst View:

Factors such as the accelerated demand for advanced diagnostic equipment and quick and effective diagnosis for TBI patients propel the noninvasive traumatic brain injury diagnostic equipment market growth. However, the adverse effects of contrast medium/agent impede the growth of the market.

Growth Drivers:

Accelerated Demand for Advanced Diagnostic Equipment Drives Noninvasive Traumatic Brain Injury Diagnostic Equipment Market Growth

According to the Medical Research Council 2022 report, 10 million people across the world sustain traumatic brain injury (TBI) annually. Likewise, the Headway 2024 report revealed that acquired brain injury (ABI) is rising in the UK; a total of 356,699 hospital admissions were registered due to ABI in the UK from 2019 to 2020. Among these, the male population was 1.5 times higher than females admitted to hospitals for a head injury. As per The Economist Intelligence Unit report, the global healthcare burden of TBI is estimated to be around US$ 400 billion annually. The most common form of ABI is TBI due to an accident or stroke. The Centers for Disease Control and Prevention (CDC) report revealed that an estimated 1.7 million TBI-related emergency department visits, hospitalizations, and deaths occur annually in the US, especially among adults aged 75 years and older as they are at high risk of falling due to problems with gait and balance. Also, road accidents are the leading cause of TBI-related deaths in the US and are highest among adults aged 20–24 years. Therefore, manufacturers are developing innovative products to diagnose TBI. In October 2023, bioMérieux announced Conformité Européenne (CE) marking for "VIDAS TBI (GFAP, UCH-L1)," a test intended to improve the assessment of patients suffering from mild traumatic brain injury (mTBI). VIDAS TBI (GFAP, UCH-L1) test measures the concentration of glial fibrillary acidic protein (GFAP) and ubiquitin C-terminal hydrolase L1 (UCH-L1)—the two brain biomarkers released into the bloodstream starting from the first hour following a brain injury. It is an easy-to-interpret test providing a test window of up to 12 hours after injury, which can help in shortening total emergency department workup time. The product's commercial launch was in 2023 for selected European, North African, and South American markets; the global launch is planned in 2024 or 2025.

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Get 10% FREE CUSTOMIZATION

Noninvasive Traumatic Brain Injury Diagnostic Equipment Market: Strategic Insights

Market Size Value in	US$ 1.349 billion in 2022
Market Size Value by	US$ 3.541 billion by 2030
Growth rate	CAGR of 12.8% from 2022 to 2030
Forecast Period	2022-2030
Base Year	2022

Mrinal

Have a question?

Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

 Speak to Analyst

Report Segmentation and Scope:

The “noninvasive traumatic brain injury diagnostic equipment market analysis” has been carried out by considering the following segments: technique, device type, and end user.

Segmental Analysis:

By technique, the noninvasive traumatic brain injury diagnostic equipment market is segmented into electroencephalography, eye tracking and near-infrared spectroscopy, magnetoencephalography, transcranial magnetic stimulation, cerebral metabolic rate of oxygen, magnetic resonance imaging, intracranial pressure, brain-computer interface, cerebral metabolic rate of oxygen, and others. The magnetic resonance imaging segment held the largest market share in 2022. The eye tracking and near-infrared spectroscopy segment is anticipated to register the highest CAGR of 14.3% during the forecast period.

The noninvasive traumatic brain injury diagnostic equipment market, by device type, is divided into imaging devices and monitoring devices. The imaging devices segment held a larger market share in 2022 and monitoring devices are anticipated to register a higher CAGR of 14.5% during the forecast period.

The noninvasive traumatic brain injury diagnostic equipment market, by end user, is categorized into hospitals & clinics, diagnostic centers, and others. The hospitals & clinics segment held the largest market share in 2022 and diagnostic centers are anticipated to register the highest CAGR of 13.4% during the forecast period. Emergence of Portable Nonivasive Monitoring Devices to Diagnose TBI Patients Acts as a Noninvasive Traumatic Brain Injury Diagnostic Equipment Future Trend

New noninvasive methods for monitoring tissue metabolism can help improve the diagnosis and monitoring of brain conditions such as concussions, stroke, and TBI, owing to which patients can recover more quickly. The consequences of TBI resulted in increasing healthcare burden costs, accounting for US$ 76.5 billion annually, as per the BrainScope company white paper. The installation of "BrainScope One" in less expensive care settings—e.g., emergency department and community settings (including urgent care centers)—may result in a significant reduction of healthcare costs by up to 32.2%, as per the findings revealed in the white paper. BrainScope One aids in eliminating unnecessary CT scans, thereby reducing healthcare costs for TBI. Thus, advancements in diagnosis and monitoring of brain conditions discovery will likely bring new avenues for noninvasive traumatic brain injury diagnostic equipment market trends in the coming years.

Regional Analysis:

The scope of the noninvasive traumatic brain injury diagnostic equipment market report covers North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa. In 2022, North America held the largest noninvasive traumatic brain injury diagnostic equipment market share. The US is the largest contributor to the market in North America. The Centers for Disease Control and Prevention (CDC) report revealed that an estimated 2.5 million people suffer from TBI annually in the US. According to the KNAPP & ROBERTS report, 1 in every 6 Americans live with TBI-related disability in the US alone, accounting for approx. 5.3 million. With the rising prevalence of TBI, the economic cost accounts for US$ 76.5 billion. Among US$ 76.5 billion, US$ 11.5 billion accounts for direct medical costs and nearly US$ 65 billion for indirect costs. The leading causes of TBI include falls (45%), motor vehicle crashes (14.3%), assaults (10.7%), and unknown (19.0%).

Additionally, Sense Neuro Diagnostics announced clearance to conduct clinical trials for hemorrhage detection. The new trial approved by the FDA Division of Neurosurgical, Neurointerventional, and Neurodiagnostic Devices began in June 2023, including up to 300 patients in 30 US, Canada, and Indian sites. This noninvasive technology has the potential to collect 360 data points within 2.5 seconds to detect brain hemorrhage or stroke type, thereby helping quick response by physicians, emergency department personnels, neuro ICU teams, and military field hospitals assessing and monitoring TBI. Furthermore, innovative product launches by US-based companies to improve outcomes of diagnosis of patients suffering from TBI stimulate the noninvasive traumatic brain injury diagnostic equipment market growth.

Industry Developments and Future Opportunities:

The noninvasive traumatic brain injury diagnostic equipment market forecast can help stakeholders in this marketplace plan their growth strategies. A few strategic developments by leading players operating in the noninvasive traumatic brain injury diagnostic equipment market are listed below:

• In April 2022, Imeka announced a collaboration with GE Healthcare to expand the capabilities of magnetic resonance imaging (MRI) and advance precision medicine for brain health. GE will integrate Imeka's noninvasive neuroimaging technology into the BrainWave advanced diffusion processing, allowing researchers and clinicians to analyze injuries by MRI signals into the brain in great detail.

Noninvasive Traumatic Brain Injury Diagnostic Equipment Market Report Scope

Competitive Landscape and Key Companies:

GE HealthCare Technologies Inc, Elekta AB, Integra LifeSciences Holdings Corp, Natus Medical Inc, Raumedic AG, BrainScope Co Inc, Luciole Medical AG, Soterix Medical Inc, Medtronic Plc, Vivonics Inc, NanoDx Inc, Compumedics Ltd, Sense Diagnostics Inc, NeuraSignal Inc, and Neurovigil Inc are among the prominent companies profiled in the noninvasive traumatic brain injury diagnostic equipment market report. These companies focus on developing new technologies, upgrading existing products, and expanding their geographic presence to meet the growing consumer demand worldwide.